POWAY, CA--(Marketwire - February 21, 2013) - Digirad Corporation (NASDAQ: DRAD), a leading provider of diagnostic imaging products, and personnel and equipment leasing services, today announced the launch of their Molecular Breast Imaging Accessory for the ergo™ Imaging System, further expanding the clinical flexibility of the ergo™ Imaging System for applications in the area of women's health, as well as in nuclear medicine where the ergo™ Imaging System is currently used for a wide variety of clinical applications.
The introduction of Digirad's Molecular Breast Imaging Accessory follows the U.S. FDA 510(k) market clearance recently received for expanded use of the ergo™ Imaging System, which includes Indications for Use to aid in the evaluation of lesions in the breast and other small body parts. When used for breast imaging, the ergo™ Imaging System can be used as an adjunct to mammography or other primary breast imaging modalities.
Digirad Chief Executive Officer Todd Clyde noted that this launch marks another key step in the company's strategy to expand its imaging technology footprint in the hospital through the use of flexible, portable systems with devices that have expanded diagnostics capabilities.
"We believe the Molecular Breast Imaging Accessory fills an important market need and is a natural addition to the ergo™ Imaging System," said Clyde. "Advanced diagnostic modalities are often necessary to help clinicians identify lesions in the breast, and our new Molecular Breast Imaging Accessory provides this capability. It is a cost-effective, non-dedicated option for molecular breast imaging that enhances the clinical capabilities and operational efficiencies of the ergo™ Imaging System."
Annual mammograms are recommended by the American Cancer Society for women age 40 and older, however, not all breast cancers can be detected by mammography, especially in dense breasts. Accordingly, adjunctive diagnostics such as molecular breast imaging can help physicians spot lesions in dense and complex breast tissue.
The user-friendly design of the ergo™ Molecular Breast Imaging Accessory includes a specialized breast imaging assembly and breast-mode software to capture all normal mammographic views for direct correlation with the patient's mammogram. Additionally, it uses Digirad's industry-leading solid-state detector technology with an oversized field-of-view to obtain comprehensive, high-contrast images. The open design provides easy access for hands-free breast positioning on patients who can be seated, standing, or lying down during the examination.
Digirad is a leading provider of diagnostic imaging products, and personnel and equipment leasing services. For more information, please visit www.digirad.com. Digirad® is a registered trademark of Digirad Corporation.
About ergo™ Imaging System
The ergo™ Imaging System is Digirad's most advanced nuclear medicine camera featuring the Large Field of View (LFOV) solid-state detector. The system provides superior image contrast and clarity for general imaging. Five easy to change collimator options provide the capability to provide outstanding imaging quality for a wide range of procedures with energy ranges from 50 to 350 keV. Designed for versatility, the open gantry, long 48" reach and multiple compound motions provide enhanced positional flexibility to address various applications and patient settings. Lightweight and portable, the ergo™ Imaging System can be easily moved throughout the hospital maximizing the system's utility and convenience. The ergo™ Imaging System delivers excellent imaging without boundaries and a significant return on investment.